|
NR 4-6/2005
|
|
|
|
|
|
|
|
|
Lewofloksacyna (Oftaquix)
florochoinolon nowej generacji w zapobieganiu zapalenia wnętrza
gałki ocznej po niepowikłanych operacjach zaćmy – badanie
Europejskiego Towarzystwo Chirurgów Zaćmy i Chirurgii
Refrakcyjnej (European Society of Cataract and Refractive
Surgeons – ESCRS)
Levofloxacin (Oftaquix) a
fluoroquinolone of a new generation in prevention of the
postoperative endophthalmitis following uncomplicated cataract
surgery – the study of the European Society of Cataract and
Refractive Surgeons (ESCRS)
Justyna Izdebska, Jacek P. Szaflik
Z Katedry i Kliniki Okulistyki II Wydziału Lekarskiego Akademii
Medycznej w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik |
|
|
| Summary: |
Randomised multi-centre
european clinical trial of antibiotic prophylaxis for
endophthalmitis following cataract surgery – study has
just begun in Poland. Poland is joining one of the
largest prospective european clinical study of
antibiotic prophylaxis and the largest in ophthalmology
– the ESCRS endophthalmitis prophylaxis clinical trial.
Up to 35 000 cataract patients are going to be recruited
for this randomized, controlled, multi-centre study in
16 centres from 10 european countries. The goal is to
reduce the incidence of endophthalmitis after cataract
phacoemusification in Europe to less than 0.05% (less
than 1 per 2 000 surgeries). The patients will be
divided into four groups; different regimes of two
antibiotics: cefuroxime injected intra-camerally and
levofloxacine eye drops topically will be compared. |
| Słowa kluczowe: |
zapalenie wnętrza gałki
ocznej, endoftalmit, operacje zaćmy, badania kliniczne,
ESCRS, cefuroksym, levofloksacyna. |
| Key words: |
endophthalmitis, cataract
surgery, clinical trial, ESCRS, cefuroxime, levofloxacin. |
|
|
|
|
|
|
